Carfilzomib: A new opportunity, for WM patients

Blood

Volumn 124, Issue 4, 2014, Pages 468-469

  Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN M; RITUXIMAB;

AMYLOIDOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD VISCOSITY; CRYOGLOBULINEMIA; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GENE MUTATION; HUMAN; KIDNEY FAILURE; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; MYELOMA; NEUROTOXICITY; NOTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; WALDENSTROM MACROGLOBULINEMIA;

EID: 84905404672     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-578625     Document Type: Note

References (9)

1. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014;124(4):503-510.
2. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Bortezomib in Waldenström's Macroglobulinemia. Haematologica. 2005;90:1655-1658.
3. Chen CI, Kouroukis CT, White D, et al; National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570-1575.
4. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27(23):3830-3835.
5. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):3276-3282.
6. Treon SP, Yang G, Hanzis C, et al. Attainment of complete/very good partial response following rituximabbased therapy is an important determinant to progressionfree survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011;154(2):223-228.
7. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753-1761.
8. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791-2796.
9. Hunter ZR, Manning RJ, Hanzis C, et al. IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica. 2010;95(3):470-475.